Dilda Pierre J, Don Anthony S, Tanabe Kara M, Higgins Vincent J, Allen John D, Dawes Ian W, Hogg Philip J
Center for Vascular Research, University of New South Wales, Department of Haematology, Prince of Wales Hospital, Sydney, Australia.
J Natl Cancer Inst. 2005 Oct 19;97(20):1539-47. doi: 10.1093/jnci/dji316.
The synthetic tripeptide arsenical 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) is an angiogenesis inhibitor that targets the mitochondria of actively dividing but not quiescent endothelial cells, arresting their proliferation and causing apoptosis. Normal endothelial cells are much more sensitive to GSAO than tumor cells. To elucidate the mechanism of tumor cell resistance, we identified yeast genes that are necessary for resistance to GSAO.
We screened a genome-wide set of 4546 Saccharomyces cerevisiae deletion strains to identify GSAO-sensitive strains. We then examined GSAO accumulation in and proliferation activity of endothelial cells (BAECs) and tumor cells treated with GSAO and modulators of pathways and proteins identified in the yeast screen. We also examined GSAO effects on proliferation of mammalian cells transfected with transporter protein constructs.
Eighty-eight deletion strains were sensitive to GSAO. The most sensitive strains had deletions of genes whose products are involved in vacuolar function (corresponding to drug transport in mammalian cells) and glutathione synthesis. BAECs were more sensitive to GSAO than tumor cells, and cell sensitivity to GSAO was approximately proportional to cellular glutathione levels. Treatment of BAECs and tumor cells with MK-571, an inhibitor of multidrug resistance-associated protein (MRP), or with buthionine sulfoximine, an inhibitor of glutathione synthesis, increased their sensitivity to GSAO. Mammalian cells transfected with MRP1 or MRP2 were resistant to GSAO, whereas cells transfected with MRP3, MRP4, MRP5, P-glypoprotein, or breast cancer resistance protein were not.
Differences in MRP activity and cellular glutathione levels contribute to the selectivity of GSAO for endothelial versus tumor cells. MRP1 and/or MRP2 may transport GSAO from resistant cells, with glutathione acting as a cotransporter. Genetic screening in yeast is a powerful tool for understanding drug action in mammalian cells.
合成三肽砷化合物4-(N-(S-谷胱甘肽乙酰基)氨基)苯亚砷酸氧化物(GSAO)是一种血管生成抑制剂,其作用靶点是活跃分裂而非静止的内皮细胞的线粒体,可阻止其增殖并导致凋亡。正常内皮细胞对GSAO的敏感性远高于肿瘤细胞。为阐明肿瘤细胞耐药的机制,我们鉴定了对GSAO耐药所必需的酵母基因。
我们筛选了一组全基因组的4546个酿酒酵母缺失菌株,以鉴定对GSAO敏感的菌株。然后我们检测了用GSAO以及在酵母筛选中鉴定出的信号通路和蛋白质调节剂处理后的内皮细胞(BAECs)和肿瘤细胞中GSAO的积累及其增殖活性。我们还检测了GSAO对转染了转运蛋白构建体的哺乳动物细胞增殖的影响。
88个缺失菌株对GSAO敏感。最敏感的菌株缺失了其产物参与液泡功能(相当于哺乳动物细胞中的药物转运)和谷胱甘肽合成的基因。BAECs对GSAO的敏感性高于肿瘤细胞,细胞对GSAO的敏感性大致与细胞内谷胱甘肽水平成正比。用多药耐药相关蛋白(MRP)抑制剂MK-571或谷胱甘肽合成抑制剂丁硫氨酸亚砜胺处理BAECs和肿瘤细胞,可增加它们对GSAO的敏感性。转染了MRP1或MRP2的哺乳动物细胞对GSAO耐药,而转染了MRP3、MRP4、MRP5、P-糖蛋白或乳腺癌耐药蛋白的细胞则不耐药。
MRP活性和细胞内谷胱甘肽水平的差异导致了GSAO对内皮细胞和肿瘤细胞的选择性。MRP1和/或MRP2可能将GSAO从耐药细胞中转运出来,谷胱甘肽作为共转运体发挥作用。酵母中的基因筛选是理解药物在哺乳动物细胞中作用的有力工具。